NL-OMON21267暂停不适用
Acute cardiometabolic risks during treatment with haloperidol in elderly patients.
Tergooiziekenhuizen0 个研究点目标入组 128 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 发起方
- 入组人数
- 128
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Age 70 years and older admitted for hip fracture or other fall-related fractures;
- •2. Inclusion within 72 hours after admission;
排除标准
- •1. Use of an antipsychotic agent within 90 days before admission;
- •2. Start or dose change in of any anticoagulants, Qtc prolongation drugs, antidiabetic drugs, antihypertensive drugs or cholesterol lowering drugs;
研究者
相似试验
撤回
不适用
Acute cardiometabolic adverse effects during treatment with haloperidol in elderly patientsadverse effect10012221NL-OMON38934Tergooiziekenhuizen Hilversum150
撤回
不适用
Acute cardiometabolic risks during treatment with haloperidol in elderly patients.NL-OMON37239Tergooiziekenhuizen Hilversum128
已完成
不适用
Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial InfarctionMetabolic SyndromeCoronary Artery DiseaseNCT02054390Ankara University459
已完成
不适用
Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)Cardiac DiseaseCancerNCT03530215Groupe Hospitalier Pitie-Salpetriere500,000
招募中
不适用
Metabolic adverse events and comorbidity in chronic rheumatoid arthritis patients.rheumatoid artritiscardiovascular diseasesglucose intoleranceinsuline resistanceischemic heart diseaseheart failureNL-OMON20413Top Institute Pharma300